Westpac Banking Corp
WBC
CommBank
CBA
Fortescue Ltd
FMG
Rio Tinto Ltd
RIO
National Australia Bank Ltd
NAB
AU Stock MarketDetailed Quotes
IMU Imugene Ltd
- 0.036
- 0.0000.00%
20min DelayMarket Closed Dec 27 16:00 AET
272.41MMarket Cap-1.71P/E (Static)
0.037High0.036Low2.80MVolume0.036Open0.036Pre Close101.21KTurnover0.13052wk High0.05%Turnover Ratio7.57BShares0.03552wk Low-0.021EPS TTM225.10MFloat Cap38.521Historical HighLossP/E (Static)6.25BShs Float0.004Historical Low-0.021EPS LYR2.78%Amplitude--Dividend TTM2.25P/B1Lot Size--Div YieldTTM
About Imugene Ltd Company
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Company Profile
SymbolIMU
Company NameImugene Ltd
Founded1986
MarketASX
Employees3
Fiscal Year Ends06-30
Address4-6 Bligh Street Suite 12.01, Level 12
CitySydney
CountryAustralia
Zip Code2000
Websitehttps://www.imugene.com
Share RegistryAUTOMIC REGISTRY SERVICES
477 Collins Street, MELBOURNE, VIC, AUSTRALIA, 3000
1300 288 664
Company Executives
- Name
- Position
- Salary
- Leslie Chong
- Director, Chief Executive Officer and Managing Director
- --
- Paul E Hopper
- Executive Chairman of the Board
- --
- Dr. Kimberlee Cobleigh Drapkin, PhD
- Director
- --
- Dr. Jens Eckstein
- Independent Director
- --
- Dr. Jakob Dupont, M.D.
- Independent Director
- --
- Dr. Lesley Russell, M.R.C.P.,MB.Ch.B.
- Independent Director
- --
